Efficacy and Safety of Phosphatidylinositol 3-kinase Inhibitors for Patients with Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Yi WangXianling DuHongqiang XinRuimin Xu

Published in: Current cancer drug targets (2024)

PI3K inhibitors had better efficacy than the present standard of concern for patients with breast cancer, especially among patients with PIK3CA mutations. Hence, clinicians and oncologists can provide this drug for the target population with extra caution for diabetes patients.

Keyphrases

end stage renal disease
ejection fraction
type diabetes
newly diagnosed
chronic kidney disease
systematic review
prognostic factors
emergency department
patient reported outcomes
metabolic syndrome
adverse drug
patient reported
electronic health record